Related Experiment Video
Updated: Mar 13, 2026
07:34
Modified Annexin V/Propidium Iodide Apoptosis Assay For Accurate Assessment of Cell Death
Published on: April 24, 2011
105.3K
Value Added by the Prevnar 13 Childhood Immunization Program in Alberta, Canada (2010-2015)
Arianna Waye1, Anderson W Chuck2,3
1Institute of Health Economics, 1200 10405 Jasper Avenue, Edmonton, AB, T5J 3N4, Canada. awaye@ihe.ca.
Drugs - Real World Outcomes
|October 18, 2016
Summary
Alberta
Area of Science:
- Public Health
- Immunization Programs
- Infectious Disease Epidemiology
Background:
- Streptococcus pneumoniae causes respiratory infections, meningitis, and bacteremia.
- Alberta introduced Prevnar 7 (PCV7) in 2002 and replaced it with Prevnar 13 (PCV13) in 2010.
- PCV13 targets six additional S. pneumoniae serotypes compared to PCV7.
Purpose of the Study:
- To estimate the impact of the PCV13 immunization program on disease burden in Alberta.
- To assess the associated changes in healthcare costs following PCV13 introduction.
Main Methods:
- Utilized serotype-specific passive surveillance data for invasive pneumococcal disease (IPD) in Alberta.
- Estimated IPD incidence for PCV13-specific serotypes pre- (2000-2009) and post- (2011-2015) PCV13 introduction.
- Calculated changes in direct health service costs based on estimated case reductions.
Main Results:
- Significant decline in IPD cases caused by PCV13-added serotypes across all age groups post-PCV13 introduction.
- Estimated 1.6 IPD cases prevented annually per 100,000 population.
- Anticipated reduction in direct health service costs and indirect benefits for individuals over 20 years old.
Conclusions:
- Replacing PCV7 with PCV13 in Alberta's public immunization program is estimated to save CAN$3.5 million in direct healthcare costs by 2015.
- The PCV13 vaccine demonstrates a positive impact on disease burden and healthcare expenditure in Alberta.
